je.st
news
Tag: outperformed
Last week in telecoms: Tele Columbus outperformed, Altice underperformed
2018-01-22 09:12:00| Telecompaper Headlines
(Telecompaper) Relevant news for telecoms stocks in West & Central Europe was limited during week 3 of 2018 as investors were awaiting the Q4 reporting season. The biggest movers ranged from Drillisch and Tele Columbus (+2.8% and +4.3%) to BT Group (-3.9%) and Altice (-2.4%).
Tags: week
columbus
tele
telecoms
High ROIC Stocks Outperformed In 2008
2015-12-18 22:41:27| Toys - Topix.net
What do toy company Hasbro , retail giant Wal-Mart , tax preparer H&R Block , auto parts store AutoZone , and biotech companies Gilead , Amgen , and Celgene all have in common? They are the only surviving S&P 500 stocks to rise 10% or more in 2008. In the midst of a collapsing market and the subsequent damage, these seven stocks made good money for investors.
Tags: high
stocks
outperformed
stocks high
High ROIC Stocks Outperformed In 2008
2015-12-18 22:19:50| Auto Parts - Topix.net
What do toy company Hasbro , retail giant Wal-Mart , tax preparer H&R Block , auto parts store AutoZone , and biotech companies Gilead , Amgen , and Celgene all have in common? They are the only surviving S&P 500 stocks to rise 10% or more in 2008. In the midst of a collapsing market and the subsequent damage, these seven stocks made good money for investors.
Tags: high
stocks
outperformed
stocks high
The fund outperformed the Index for August
2015-10-01 23:41:16| Toys - Topix.net
Global equities declined in the month of August, reacting, in part, to China's surprising yuan devaluation and evidence of slower economic growth in China. Every developed equity market in the MSCI World Index delivered negative returns this month, and emerging markets underperformed developed markets.
Tags: index
august
fund
outperformed
Mylan: Outperformed S&P 500 Since June, And Shows No Signs Of Slowing
2015-01-22 16:03:15| Biotech - Topix.net
Mylan has shown alpha returns over the past year, beating the S&P 500 by approximately 4% in the past four months. The outlook for the drug device combination products industry is expected to grow at a CAGR rate of 7.9% through to 2019.